"シオノギ" の関連情報検索結果
Shionogi to Announce Personnel Reassignment| 塩野義製薬 - Shionogi
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial Reuters
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan - GlobeNewswire
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan GlobeNewswire
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout - BioCentury
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout BioCentury
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan - Sleep Review
Nxera Pharma Partners with Shionogi for Quviviq Distribution in Japan Sleep Review
Is Weakness In Shionogi & Co., Ltd. (TSE:4507) Stock A Sign That The Market Could be Wrong Given ...
Is Weakness In Shionogi & Co., Ltd. (TSE:4507) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? Simply Wall St
Shionogi presents largest global real-world evidence study of cefiderocol - The Pharma Letter
Shionogi presents largest global real-world evidence study of cefiderocol The Pharma Letter
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech
After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M Fierce Biotech
Notice of Head Office Relocation| 塩野義製薬 - Shionogi
IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrat...
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentation...
The public wants Medicare to cover obesity drugs - STAT
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment - The Hearing Review
Cilcare and Shionogi Announce Option Agreement for Hearing Disorder Treatment The Hearing Review
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement f...
David Benadon| 塩野義製薬 - Shionogi
David Benadon| 塩野義製薬 Shionogi
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
Recognized with the Double A List for Leadership in Corporate Transparency and Performance on Cli...
Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadersh...
Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Co...
Shionogi's antiviral comes up short in global COVID-19 trial - FiercePharma
Shionogi's antiviral comes up short in global COVID-19 trial FiercePharma
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Includi...
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter - The Pharma Letter
Nxera Pharma and Shionogi partner on Quviviq | Pharmaceutical | The Pharmaletter The Pharma Letter
Shionogi files NDA in Japan for zuranolone in MDD - The Pharma Letter
Shionogi files NDA in Japan for zuranolone in MDD The Pharma Letter
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Q...
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household T...
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial Wiley Online Library
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models - BioWorld Online
Shionogi’s MGAT2 inhibitor improves metabolism in obesity models BioWorld Online
Japan's Shionogi seeks China approval for superbug-fighting antibiotic - Nikkei Asia
Japan's Shionogi seeks China approval for superbug-fighting antibiotic Nikkei Asia
Shionogi’s COVID-19 drug misses endpoint in global phase III - BioWorld Online
Shionogi’s COVID-19 drug misses endpoint in global phase III BioWorld Online
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill - Nikkei Asia
Japan's Shionogi eyes early 2025 for U.S. release of COVID pill Nikkei Asia
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1...
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Addre...
Nxera Pharma Partners with Shionogi on Insomnia Drug - TipRanks
Nxera Pharma Partners with Shionogi on Insomnia Drug TipRanks
Shionogi presents new GLP-1R agonists for obesity and diabetes - BioWorld Online
Shionogi presents new GLP-1R agonists for obesity and diabetes BioWorld Online
Shionogi commences Phase III monovalent Covid-19 vaccine trial - Clinical Trials Arena
Shionogi commences Phase III monovalent Covid-19 vaccine trial Clinical Trials Arena
Shionogi's COVID Drug Stumbles, Yet Eyes Future Success - Finimize
Shionogi's COVID Drug Stumbles, Yet Eyes Future Success Finimize
Novel COVID-19 Antiviral Ensitrelvir Provides Earlier Symptom Relief in Phase 3 Trial - Infectiou...
Novel COVID-19 Antiviral Ensitrelvir Provides Earlier Symptom Relief in Phase 3 Trial Infectious Disease Advisor
Japan's Shionogi announces $150 M deal to develop first oral therapy for Pompe Disease - BSA bureau
Japan's Shionogi announces $150 M deal to develop first oral therapy for Pompe Disease BSA bureau
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's lat...
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move The Business Journals
Shionogi’s oral COVID-19 antiviral wins full approval in Japan - BioWorld Online
Shionogi’s oral COVID-19 antiviral wins full approval in Japan BioWorld Online
New Antivirals for Today's COVID-19: Ensitrelvir and Beyond - Infectious Disease Special Edition
New Antivirals for Today's COVID-19: Ensitrelvir and Beyond Infectious Disease Special Edition
Dialogue 2021|シオノギ製薬(塩野義製薬) - Shionogi
Dialogue 2021|シオノギ製薬(塩野義製薬) Shionogi
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression - BioWorld Online
Shionogi, Fronteo developing AI diagnostic support models for dementia, depression BioWorld Online
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in ...
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open Business Wire
Agency 100 2024: FCBCure - MM+M Online
Agency 100 2024: FCBCure MM+M Online
Keiko Tone - Shionogi - Board Member - The Association of the British Pharmaceutical Industry
Keiko Tone - Shionogi - Board Member The Association of the British Pharmaceutical Industry
SHIONOGI Infectious Disease Weeks - Shionogi
SHIONOGI Infectious Disease Weeks Shionogi
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health (NIH) (.gov)
Generative AI turns conference attendees into infectious disease warriors - MM+M Online
Generative AI turns conference attendees into infectious disease warriors MM+M Online
Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership...
Advancing Malaria Research: Nagasaki University and Shionogi Extend Industry-Academia Partnership nagasaki-u.ac.jp
Address the problem of antimicrobial resistance (AMR) | Sustainability | Shionogi & Co., Ltd. - S...
Address the problem of antimicrobial resistance (AMR) | Sustainability | Shionogi & Co., Ltd. Shionogi
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use - BSA bureau
Taiwan approves Japan-based Shionogi's influenza drug for paediatric use BSA bureau
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss - BSA bureau
Japan's Shionogi inks €400 M deal with French firm Cilcare to address hearing loss BSA bureau
Masahiro Fujita - Shionogi
Masahiro Fujita Shionogi
European Commission offers hope for misunderstood intellectual disability and autism condition, F...
European Commission offers hope for misunderstood intellectual disability and autism condition, FXS OutSourcing-Pharma.com
Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...
Shionogi Announces Agreement With SOBI - European Pharmaceutical Manufacturer
Shionogi Announces Agreement With SOBI European Pharmaceutical Manufacturer
Margaret Borys - Shionogi
Margaret Borys Shionogi
Mother to Mother SHIONOGI Project - Shionogi
Mother to Mother SHIONOGI Project Shionogi
Annual Report / Integrated Report / Environment Report | IR Library | Shionogi & Co., Ltd. - Shio...
Annual Report / Integrated Report / Environment Report | IR Library | Shionogi & Co., Ltd. Shionogi
Partnering to Bring Meaningful Science to Patients - Shionogi
“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamm...
Tadashi Hara - Shionogi
Tadashi Hara Shionogi
Message from Top Management - Shionogi
Message from Top Management Shionogi
Medium-Term Business Plan STS2030 Revision(FY2023 – FY2030) | Business Strategy | Shionogi & Co...
Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug - BSA...
Shionogi and Osaka University unveils a new joint research lab to review anti-COVID-19 drug BSA bureau
History - Shionogi
History Shionogi
Shionogi Certified as the First Eco-First Company in the Pharmaceutical Industry of Environmental...
What we stand for: Takeki Uehara - Shionogi
What we stand for: Takeki Uehara Shionogi
Climate Change | Environment | Shionogi & Co., Ltd. - Shionogi
Climate Change | Environment | Shionogi & Co., Ltd. Shionogi
Nathan McCutcheon - Shionogi
Nathan McCutcheon Shionogi
New data from Japan shows early resolution of common Covid-19 symptoms - BioPharma-Reporter.com
New data from Japan shows early resolution of common Covid-19 symptoms BioPharma-Reporter.com
Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malari...
Japan’s Nagasaki University and Shionogi extend industry-academia partnership to eliminate malaria BSA bureau
Research Topics - Shionogi
Research Topics Shionogi
“Gamma wave sound weather forecast” using “gamma wave sound” jointly developed by Pixie Dust Tech...
“Gamma wave sound weather forecast” using “gamma wave sound” jointly developed by Pixie Dust Technologies and Shionogi & Co., starts regular broadcasting on Japan’s first radio program, Bunka Broadcasting Pixie Dust Technologies, Inc.
Taiwan FDA approves Shionogi's FETROJA for treating complicated urinary tract infections - BSA bu...
Taiwan FDA approves Shionogi's FETROJA for treating complicated urinary tract infections BSA bureau
Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. - Shionogi
Diversity and inclusion | Attractive work environment | Shionogi & Co., Ltd. Shionogi
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline - BioSpace
Shionogi Buys Qpex Biopharma for $140M, Expands Antimicrobial Pipeline BioSpace
A&O advises Shionogi on its strategic joint venture with Apnimed for the development of therapies...
Financial Highlights | Investors | Shionogi & Co., Ltd. - Shionogi
Financial Highlights | Investors | Shionogi & Co., Ltd. Shionogi
Shionogi has been Selected as One of the Excellent Integrated Reports by the GPIF's Domestic Equi...
Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial...
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters
Japan's Shionogi says COVID-19 pill shows rapid clearance of virus Reuters
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat - ...
Antimicrobial resistance: Shionogi advocates policy change to address the public health threat Nature.com
The race for obesity drug assets heats up - pharmaphorum
The race for obesity drug assets heats up pharmaphorum
Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022 - Shionogi
Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022 Shionogi
Staying ahead of antimicrobial resistance - Nature.com
Staying ahead of antimicrobial resistance Nature.com
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine - Fierc...
Shionogi splashes $100M on F2G's rare fungal disease drug to unlock new class of medicine Fierce Biotech
Improving access to healthcare services in developing countries - Shionogi
Improving access to healthcare services in developing countries Shionogi
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean spor...
WADA and Shionogi pharmaceutical company sign MOU formalizing collaboration to protect clean sport WADA
Initiatives to support people with neurodevelopmental disorders | Society | Shionogi & Co., Ltd. ...
Initiatives to support people with neurodevelopmental disorders | Society | Shionogi & Co., Ltd. Shionogi
Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against B...
Fierce Pharma Asia—Shionogi's Qpex buy; Takeda's rare disease win; AbbVie's patent suit against BeiGene FiercePharma
Shionogi Falls After a Panel Postpones Decision on Covid Pill - Bloomberg
Shionogi Falls After a Panel Postpones Decision on Covid Pill Bloomberg
Shionogi’s Covid-19 Pill Ready to Move to Final Trial Phase - Bloomberg
Shionogi’s Covid-19 Pill Ready to Move to Final Trial Phase Bloomberg
UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs - Bloomberg
UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs Bloomberg
Shionogi Jumps After Covid-19 Antiviral Pill Seen Effective - Bloomberg
Shionogi Jumps After Covid-19 Antiviral Pill Seen Effective Bloomberg
Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral ...
Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir ACS Publications
Japanese drugmaker urges G7 to fix infectious diseases market - Financial Times
Japanese drugmaker urges G7 to fix infectious diseases market Financial Times
Japan's Shionogi starts phase III clinical trial in Vietnam for Covid-19 vaccine - Reuters
Japan's Shionogi starts phase III clinical trial in Vietnam for Covid-19 vaccine Reuters
Second Term Project:Mother to Mother SHIONOGI Project - Shionogi
Second Term Project:Mother to Mother SHIONOGI Project Shionogi